LPM-570065
- Generic Name
- LPM-570065
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets
Phase 4
Not yet recruiting
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 736
- Registration Number
- NCT06426485
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder
Not Applicable
Completed
- Conditions
- Major Depression Disorder
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 84
- Registration Number
- NCT06278038
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder
Not Applicable
Recruiting
- Conditions
- Anhedonia
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Jiangsu Province Nanjing Brain Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06270433
- Locations
- 🇨🇳
Nanjing Brian Hospital, Nanjing, Jiangsu, China
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
Phase 4
Recruiting
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 15
- Registration Number
- NCT06026917
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression
Phase 4
Not yet recruiting
- Conditions
- Somatic Symptom
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 60
- Registration Number
- NCT05849272
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
A Relative Bioavailability Food Effect Study of LY03005
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT03822065
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
A Study of LY03005 vs Pristiq
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03733574
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03357796
- Locations
- 🇺🇸
Clinilabs, Inc., Eatontown, New Jersey, United States
Pilot BA Study of New LY03005 vs Pristiq
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02988024
- Locations
- 🇺🇸
Clinilabs, Inc., Eatontown, New Jersey, United States
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Phase 1
Completed
- Conditions
- Major Depressive Disorder, Recurrent, Unspecified
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT02271412
- Locations
- 🇺🇸
PRA Health Sciences, Marlton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath